The clinical relevance of different antiphospholipid antibody profiles in pediatric rheumatology patients.

Jheel Pandya, Karen Onel, Doruk Erkan

Open access · goldAbstract read

In one paragraph

Article in Pediatric rheumatology online journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.5field-weighted citation impact, top 37% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children.Current opinion in rheumatology · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jheel PandyaDepartment of Pediatric Rheumatology, Hospital for Special Surgery, 535 E 70th Street, 10021, New York, NY, USA. pandyaj@hss.edu.ORCID http://orcid.org/0000-0002-9863-8402

Karen OnelDepartment of Pediatric Rheumatology, Hospital for Special Surgery, 535 E 70th Street, 10021, New York, NY, USA.

Doruk ErkanHospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Disease, Weill Cornell Medicine, 535 E70th Street, 10021, New York, NY, USA.

Hospital for Special Surgery · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti-β

findingsIn this single center retrospective cohort study, based on the screening of our pediatric (age ≤ 18) rheumatology electronic medical records (2016-2022), we identified patients who had at least one "positive" aPL (lupus anticoagulant [LA], aCL IgG/M, or aβ

conclusionAn initial high-risk aPL profile was persistent in approximately 90% of our cohort, a third of whom had thrombosis, and half had non-thrombotic aPL manifestations. Our results underscore the need for a large-scale effort to better characterize aPL-related manifestations in pediatric patients with persistent high-risk aPL-profiles.

Indexed as

Antibodies, AnticardiolipinAntibodies, Antiphospholipidbeta 2-Glycoprotein IAdolescentAntiphospholipid SyndromeChildChild, PreschoolClinical RelevanceFemaleHumansLupus Coagulation InhibitorMaleRetrospective StudiesRheumatic DiseasesThrombosisAntibodies, AnticardiolipinAntibodies, Antiphospholipidbeta 2-Glycoprotein ILupus Coagulation InhibitorAntiphospholipid syndromePediatricsRheumatologyThrombosis

Identifiers

PMID38671480

DOI10.1186/s12969-024-00954-8

PMCPMC11046946

OpenAlexW4395668733

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.